MENLO PARK, Calif.—Eyecare tech company Sight Sciences, Inc. (Nasdaq: SGHT) reported financial results yesterday for the second quarter ended June 30, 2026, while raising its revenue guidance and reducing its adjusted operating expense guidance for full year 2026. Revenue for the second quarter of 2026 was $23.4 million, an increase of 20 percent compared with the same period in the prior year. Net loss for Q2 was $4.4 million, a 63 percent improvement from $11.9 million for the same period in 2025.
Growth was driven primarily by the company’s Interventional Glaucoma segment, which posted revenue of $20.7 million, a rise of 8 percent versus the prior year period that was fueled by increased volume. Adding to that was revenue from the Interventional Dry Eye segment, which at $2.7 million marked a 704 percent increase versus $0.3 million in the same period in the prior year, the company said. Growth in this segment was powered primarily by increased volumes and higher average selling prices.
“We delivered a strong second quarter, with revenue growth accelerating to 20 percent year-over-year, and both business segments contributing meaningfully to the robust growth. Our performance reflects the growing interventional mindset across glaucoma and dry eye disease, the strength of our market-leading technologies, and the focus of our experienced commercial teams in partnering with customers to make interventional eyecare the new standard of care,” said Paul Badawi, co-founder and CEO of Sight Sciences. “Based on our year-to-date performance and business momentum, we are raising our 2026 revenue guidance, reducing our adjusted operating expense guidance, and we believe we are well positioned for the second half of the year.”
Gross profit for the second quarter of 2026 was $21.4 million compared to $16.6 million in the same period in the prior year, with gross margin reaching 91 percent, including a $1.4 million benefit from tariff refunds received in the quarter, the company said. Excluding tariff refunds, gross margin was 86 percent compared with 85 percent in the same period in the prior year.
Total operating expenses fell 11 percent to $25.3 million in the second quarter of 2026 from $28.3 million in the prior year period, driven by lower personnel expenses and stock-based compensation, the company said. Research and development expenses decreased 43 percent to $2.5 million from $4.4 million. Selling, general, and administrative expenses dropped 5 percent to $22.8 million from $23.9 million.
Cash and cash equivalents totaled $79.8 million and total long-term debt was $40.0 million (excluding unamortized debt discount and debt issuance costs) as of June 30, 2026, compared with $85.0 million and $40.0 million, respectively, as of March 31, 2026.
The company raised its revenue guidance for full year 2026 to range from $88 million to $92 million, representing year-over-year growth of 14 percent to 19 percent, versus prior revenue guidance of $83 million to $89 million. This revenue guidance includes Interventional Glaucoma segment revenue of $79 million to $81 million, representing growth of 4 percent to 7 percent, and Interventional Dry Eye segment revenue of $9 million to $11 million, compared with $1.6 million in 2025.
Earlier this week, the company announced U.S. FDA 510(k) clearance of its OMNI Ultra Surgical System (OMNI Ultra) for canaloplasty followed by trabeculotomy for the reduction of intraocular pressure in adult patients with primary open-angle glaucoma, marking the newest addition to its OMNI product portfolio.
